German biopharmaceutical company CureVac (NASDAQ:CVAC) has said its potential vaccine against COVID-19, known as CVnCoV, induced an immune response in pre-clinical animal studies, Reuters news agency reported on Friday.
According to CureVac, CVnCoV produced neutralising antibodies and activated T-cells in hamsters and mice.
The new vaccine, which is being tested in humans in early and mid-stage trials, also protected the lungs of hamsters when they were exposed to a live virus, the company said.
CureVac chief technology officer Mariola Fotin-Mleczek was quoted as saying: "The pre-clinical data published today show that our COVID-19 vaccine candidate has the potential to induce an efficacious and balanced immune response, mimicking the natural immune defence and providing lung protection in a relevant challenge model."
Bavarian Nordic secures new EU contract for up to 8 million smallpox and mpox vaccine doses
Zoetis announces EU approval for Portela to relieve osteoarthritis pain in cats
4basebio synthetic DNA used in Phase I/II mRNA therapy trial
Arcturus reports interim Phase 2 data for ARCT-032 in cystic fibrosis
Sanofi reports data showing high-dose flu vaccine delivers superior protection for older adults
GC Biopharma granted CMO rights for Curevo Vaccine's shingles vaccine
TransCode acquires Polynoma and secures USD25m investment from CK Life Sciences
Wasatch BioLabs adds three Oxford Nanopore-developed research-use-only assays to service portfolio
GSK and IQVIA expand vaccine track with local data to drive targeted public health action
AstraZeneca launches online platform to expand patient access to medications
Sanofi increases Sanofi Ventures funding by USD625m to boost biotech and digital health investments
GC Biopharma submits IND application in South Korea for Phase 1 trial of COVID-19 vaccine candidate
AusperBio completes patient enrolment in two Phase II clinical trials of AHB-137